

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 November 2024 (14.11.2024)



(10) International Publication Number
WO 2024/233642 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/437 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2024/028330

(22) International Filing Date:

08 May 2024 (08.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/501,005 09 May 2023 (09.05.2023) US

(71) Applicant: **PROGENTOS THERAPEUTICS, INC.**
[US/US]; 200 Dexter Avenue, Watertown, Massachusetts
02472 (US).

(72) Inventors: **MAGAVI, Sanjay Shivayogi**; c/o PROGENTOS THERAPEUTICS, INC., 200 Dexter Avenue, Watertown, Massachusetts 02472 (US). **PARKS, Daniel J.**; c/o PROGENTOS THERAPEUTICS, INC., 200 Dexter Avenue, Watertown, Massachusetts 02472 (US). **TAIT, Bradley Dean**; c/o PROGENTOS THERAPEUTICS, INC., 200 Dexter Avenue, Watertown, Massachusetts 02472 (US). **CHO, Jinhyung**; c/o PROGENTOS THERAPEUTICS, INC., 200 Dexter Avenue, Watertown, Massachusetts 02472 (US). **KOLPAK, Adrienne**; c/o PROGENTOS THERAPEUTICS, INC., 200 Dexter Avenue, Watertown, Massachusetts 02472 (US). **SHAW, Patricia R.**; c/o PROGENTOS THERAPEUTICS, INC., 200 Dexter Avenue, Watertown, Massachusetts 02472 (US).

(74) Agent: **FRUEAUF, Jeremiah B.** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1101 K Street NW, 10th Floor, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: HETEROCYCLIC COMPOUNDS AND USES THEREOF

(57) Abstract: The present disclosure provides compounds that can specifically target a PDGFR α , and thereby, reduce and/or inhibit the activation of the receptor ("PDGFR α inhibitor"). The present disclosure also provides methods of treating a demyelinating disease using the disclosed PDGFR α inhibitors.

WO 2024/233642 A1